Cagrilintide
A long-acting amylin analogue often discussed alongside GLP-1 therapies in obesity-drug development.
This compound has a genuine development or study trail, but it is not an approved routine drug.
This profile is grouped by its dominant research and market lane, not by vendor shelf placement.
No major aliases are tracked for this profile yet.
No FDA label signal · 43 trials · 86 PubMed results
Cagrilintide has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
Cagrilintide has 19 name-matched clinical trials (highest phase: Phase 3) and 86 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What cagrilintide is
Cagrilintide is a long-acting amylin analogue being studied in obesity-focused drug development. It is commonly mentioned alongside semaglutide because combination strategies are a major theme in the metabolic-drug pipeline.
Why it matters
It expands the library beyond GLP-1-only thinking. If someone is trying to understand the next layer of obesity pharmacology, cagrilintide is one of the key names to know.
Regulatory context
Cagrilintide is not FDA approved in the United States. It belongs in the investigational bucket rather than the approved-drug bucket.
Practical reading note
Because cagrilintide often appears next to semaglutide or blend products in vendor catalogs, it is useful to separate the research narrative from branded, labeled prescription-drug status.